Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 26, 2021 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
August 05, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

Public Offering with Net Proceeds of $134.9 Million in June Strengthens Balance Sheet and Extends Cash Runway Through the End of 2024Positive Preliminary Topline Data for Phase 2a Trial of ATI-1777 in...
July 08, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021

WAYNE, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
June 09, 2021 19:55 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Announces Pricing of Public Offering of Common Stock

WAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
June 08, 2021 16:15 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Announces Proposed Public Offering of Common Stock

WAYNE, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
June 08, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

ATI-1777 Achieved Statistically Significant Result in the Primary Efficacy Endpoint at Week 4Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor ApproachATI-1777 was Generally Well...
May 17, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

WAYNE, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
May 07, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update

Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis Expected in Second Quarter of 2021Advancing ATI-450 with Planned Initiation of Phase 2b Trial for Moderate to Severe...
March 15, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

Enrollment CompletedData Expected Mid-Year 2021 WAYNE, Pa., March 15, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on...
February 25, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

Positive Preliminary Topline Data for ATI-450, an Investigational Oral MK2 Inhibitor, in Moderate to Severe Rheumatoid Arthritis Announced in January 2021ATI-450 Data Support New Oral Approach for the...